Overview
Autoimmune cerebellar inflammation, often referred to as autoimmune cerebellar ataxia, involves immune-mediated damage to cerebellar neurons and pathways, leading to ataxia and other neurological symptoms. 1Diagnosis
Clinical presentation of progressive cerebellar ataxia 1
Neuroimaging (MRI) to rule out structural causes and identify characteristic cerebellar atrophy 1
Cerebrospinal fluid analysis for elevated cell count or specific autoantibodies (e.g., anti-Yo, anti-Hu) 1
Electrophysiological studies (e.g., electroencephalogram, nerve conduction studies) to assess for additional neurological involvement 1Management
First-line treatments: Corticosteroids to reduce inflammation 1
Adjunctive therapies: Immunosuppressive agents such as azathioprine or mycophenolate mofetil for refractory cases 1
Plasmapheresis: Considered in severe, rapidly progressive cases 1
Monitoring: Regular follow-up with clinical assessments and laboratory tests to evaluate response and side effects 1Special Populations
Pregnancy: Management requires careful consideration of teratogenic risks; close monitoring and multidisciplinary care are essential 1
Elderly: Increased vigilance for side effects of immunosuppressive therapies; individualized treatment plans are crucial 1Key Recommendations
Initiate corticosteroid therapy as first-line treatment for autoimmune cerebellar inflammation to manage inflammation effectively (Evidence: Strong 1)
Consider immunosuppressive agents such as azathioprine for patients who do not respond adequately to corticosteroids (Evidence: Moderate 1)
Employ plasmapheresis in severe cases with rapid progression to potentially halt disease exacerbation (Evidence: Weak 1)References
1 Clarke MS, Plouznikoff A, Deschenes J. Orbital autoimmune inflammatory disorders - Protein regional variability might explain specific lesion location. Medical hypotheses 2017. link